Deals: Page 2
-
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Sanofi gains experimental Alzheimer’s drug through Vigil buyout
Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.
By Jacob Bell • May 22, 2025 -
Permission granted by Pfizer
China competitionPfizer buys into PD-1/VEGF competition with 3SBio deal
Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.
By Ben Fidler • May 20, 2025 -
Justin Sullivan via Getty Images
Regeneron wins bid to buy 23andMe out of bankruptcy
The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.
By Ned Pagliarulo • May 19, 2025 -
Permission granted by PHIL
Sponsored by PHILBridging the data gaps that impact retail and specialty-lite success
Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.
May 19, 2025 -
Sundry Photography via Getty Images
BioMarin to buy rare disease drugmaker Inozyme for $270M
The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug.
By Jacob Bell • May 16, 2025 -
hapabapa via Getty Images
Obesity drugsNovo to work with Septerna in hunt for oral obesity drugs
The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the latest deal Novo has struck to expand its obesity pipeline.
By Gwendolyn Wu • May 14, 2025 -
Magdalena Wygralak via Getty Images
GSK to buy liver disease drug for $1.2B
With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.
By Kristin Jensen • May 14, 2025 -
Spencer Platt via Getty Images
Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously
Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing obstacle to large acquisitions.
By Jacob Bell • May 6, 2025 -
Courtesy of Merck KGaA
Merck KGaA to buy biotech SpringWorks for $3.9B
The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.
By Ned Pagliarulo • April 28, 2025 -
Courtesy of Sanofi
China competitionSanofi licenses immune disease drugs from startup Earendil
The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23.
By Kristin Jensen • April 17, 2025 -
MadamLead via Getty Images
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial
Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.
By Jonathan Gardner • April 10, 2025 -
Artur Plawgo via Getty Images
Brain drug revivalGSK targets neurodegenerative diseases with latest licensing deal
The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.
By Jacob Bell • April 7, 2025 -
Spencer Platt via Getty Images
M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals
Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last year.
By Jacob Bell • April 4, 2025 -
Courtesy of Bluebird bio
Bluebird gets rival takeout offer from Ayrmid
The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s board still supports.
By Ben Fidler • March 28, 2025 -
Jolygon via Getty Images
China competitionMerck bets $200M on a new type of heart pill
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a).
By Jonathan Gardner • March 25, 2025 -
Courtesy of Sanofi
Immune reset
Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease
The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs aiming to “reset” the immune systems of people with inflammatory conditions.
By Kristin Jensen • March 20, 2025 -
Dr_Microbe via Getty Images
Taiho buys Swiss biotech and its ADC tech for $400M
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is superior to existing platforms.
By Delilah Alvarado • March 17, 2025 -
Christopher Furlong via Getty Images
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal
The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and autoimmune conditions.
By Ben Fidler • March 17, 2025 -
Dr_Microbe via Getty Images
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.
By Jacob Bell • March 13, 2025 -
Elizabeth Regan/BioPharma Dive
Mallinckrodt, Endo to combine in $7B deal
The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.
By Kristin Jensen • March 13, 2025 -
Permission granted by Roche
Obesity drugsRoche broadens obesity drug plans with $1.65B Zealand deal
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.
By Jonathan Gardner • March 12, 2025 -
Courtesy of CordenPharma
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.
By Jonathan Gardner • March 11, 2025 -
Meletios Verras via Getty Images
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.
By Ben Fidler • March 11, 2025 -
Jacob Bell/BioPharma Dive
Jazz expands in oncology with $935M deal for Chimerix
Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.
By Jonathan Gardner • March 5, 2025 -
Courtesy of AbbVie
Obesity drugsAbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
By Jonathan Gardner • March 3, 2025
Previous
